Thomas Hope, MD

Thomas Hope, MD, an associate professor of Radiology and director of Molecular Therapy for the Molecular Imaging and Therapeutics Clinical Section, Department of Radiology and Biomedical Imaging at the University of California, San Francisco, discusses the efficacy of the 68Ga-PSMA-11 PET for the detection of pelvic nodal metastases in patients intermediate- to high-risk prostate cancer considered for radical prostatectomy with lymph node dissection.

This prospective, single-arm phase 3 imaging trial (NCT03368547, NCT02611882, NCT02919111) was presented at the 2020 American Society of Clinical Oncology Virtual Meeting. Hope says the topline results were looking at the sensitivity and specificity compared to the patient’s histopathology.

Of the 277 patients who underwent prostatectomy in the study population, 75 (27%) of those patients had pelvic nodes at their time of surgery. Among these 75 patients, 30 of them were positive on 68Ga-PSMA-11 PET. There were 10 false positives, which were negative on the pathology but positive on the PSMA PET. This led to a sensitivity of 40% and a specificity of 95%, according to Hope. A correlation was observed with higher prostate-specific antigens and larger nodes with increased sensitivity.

<< View more resources and information regarding prostate cancer

Videos

Thomas Hope, MD, discusses the efficacy of the 68Ga-PSMA-11 PET for the detection of pelvic nodal metastases in patients intermediate- to high-risk prostate cancer considered for radical prostatectomy with lymph node dissection.

Thomas Hope, MD | Authors

Articles

Results Demonstrate Accuracy of the 68Ga-PSMA-11 PET for Prostate Cancer